Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03985189 |
Recruitment Status :
Active, not recruiting
First Posted : June 13, 2019
Last Update Posted : April 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | Drug: ME-401 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma and Roll Over Study for Subjects Who Have Participated in ME-401-004 Study |
Actual Study Start Date : | April 29, 2019 |
Estimated Primary Completion Date : | September 30, 2024 |
Estimated Study Completion Date : | September 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: ME-401
ME-401 administered orally
|
Drug: ME-401
[Phase 1 study (DLT evaluation)] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability. [Roll over study] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met. |
- Number of participants with treatment-emergent adverse events (TEAEs) [ Time Frame: Up to approximately 1 year ]
- [Phase 1 study (DLT evaluation)] Plasma concentration level of ME-401 [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Maximum plasma drug concentration (Cmax) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Area under the plasma drug concentration time curve (AUC) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Terminal half-life (t1/2) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Efficacy of ME-401 as assessed by the objective response rate (ORR) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Efficacy of ME-401 will be assessed by the duration of response (DOR) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Efficacy of ME-401 will be assessed by the progression-free survival (PFS) [ Time Frame: Up to approximately 2 years ]
- [Phase 1 study (DLT evaluation)] Efficacy of ME-401 will be assessed by the time to response (TTR) [ Time Frame: Up to approximately 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
[Phase 1 study (DLT evaluation)]
- Patients aged 20 years or older at the submission of the written informed consent form
- Patients with relapsed or refractory B-cell NHL
- Patients who have not undergone phosphatidylinositol 3-kinase inhibitor (PI3K) to date.
- Patients who have undergone Bruton's tyrosine kinase (BTK) inhibitors and have had no exacerbation during the use of BTK inhibitors.
- Patients with ECOG PS 0 or 1.
Exclusion Criteria:
[Phase 1 study (DLT evaluation)]
- Patients who underwent any major surgical treatment within 4 weeks prior to the initiation of the investigational product.
- Patients with poorly controlled diseases. The followings are the examples but the diseases will not be limited to those.
- Patients in whom any of HBV antigen/antibody, HCV antibody, HIV antibody or HTLV-1 antibody will be positive at screening test.
- Patients with active interstitial lung disease or a history thereof.
- Patients who have received the investigational products other than ME-401, systemic chemotherapy or radiotherapy within 4 weeks prior to the initiation of ME-401.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985189
Japan | |
National Hospital Organization Nagoya Medical Center | |
Nagoya, Aichi, Japan, 460-0001 | |
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital | |
Nagoya, Aichi, Japan, 466-8650 | |
Hokkaido University Hospital | |
Sapporo, Hokkaido, Japan, 060-0814 | |
Tokyo Metropolitan Komagome Hospital | |
Bunkyo-ku, Tokyo, Japan, 113-8677 | |
National Cancer Center Hospital | |
Chuo-ku, Tokyo, Japan, 104-0045 | |
The Cancer Institute Hospital of JFCR | |
Koto-ku, Tokyo, Japan, 135-8550 | |
Aomori Prefectural Central Hospital | |
Aomori, Japan, 030-8553 | |
Kyushu University Hospital | |
Fukuoka, Japan, 812-8582 | |
Okayama University Hospital | |
Okayama, Japan, 700-8558 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Kyowa Kirin Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03985189 |
Other Study ID Numbers: |
ME-401-K01 |
First Posted: | June 13, 2019 Key Record Dates |
Last Update Posted: | April 13, 2023 |
Last Verified: | April 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |